BioPorto and Roche agreed that BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c 501/c 502 analysers.
The agreement has significant strategic importance to ensure the expanded availability of NGAL tests, as well as enhancing the awareness of NGAL as a diagnostic marker for acute kidney injury, BioPorto said.
The Denmark headquartered maker of assays for underserved disease states, BioPorto, says the first cash from the agreement should be welcomed in 2019. What numbers are expected, the press release did not reveal.
It revealed that, under the terms of the agreement, Roche will have worldwide exclusive distribution rights for the NGAL test adapted for use on Roche’s cobas c 501/c 502 systems.
The NGAL Test™ is CE marked and BioPorto is currently conducting clinical studies to generate data for FDA approval, which is expected later this year.
Peter Mørch Eriksen, CEO of BioPorto, said: “I am very happy to enter into a collaboration with Roche, who as a dominant player in the diagnostic space will ensure a broad global distribution of our NGAL test to address a critical need in patient care today.”